Moderna, Inc. (MRNA) Yield on Cost (YOC): N/A
The yield on cost (YOC) for Moderna, Inc. (MRNA) is N/A.
MRNA Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
N/A
Interactive Yield on Cost Calculator
Project custom investment returns for Moderna, Inc. (MRNA) based on your custom cost basis.
Starting Yield
4.30%
Ending YOC
13.65%
Year 15 Dividend
$6.34
Cum. Dividends Recd.
$58.65
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $2.00 | — | 4.30% | $0.00 |
| Year 1 | $2.16 | +8.00% | 4.65% | $2.16 |
| Year 2 | $2.33 | +8.00% | 5.02% | $4.49 |
| Year 3 | $2.52 | +8.00% | 5.42% | $7.01 |
| Year 4 | $2.72 | +8.00% | 5.85% | $9.73 |
| Year 5 | $2.94 | +8.00% | 6.32% | $12.67 |
| Year 6 | $3.17 | +8.00% | 6.83% | $15.85 |
| Year 7 | $3.43 | +8.00% | 7.37% | $19.27 |
| Year 8 | $3.70 | +8.00% | 7.96% | $22.98 |
| Year 9 | $4.00 | +8.00% | 8.60% | $26.97 |
| Year 10 | $4.32 | +8.00% | 9.29% | $31.29 |
| Year 11 | $4.66 | +8.00% | 10.03% | $35.95 |
| Year 12 | $5.04 | +8.00% | 10.83% | $40.99 |
| Year 13 | $5.44 | +8.00% | 11.70% | $46.43 |
| Year 14 | $5.87 | +8.00% | 12.64% | $52.30 |
| Year 15 | $6.34 | +8.00% | 13.65% | $58.65 |
Yield on Cost (YOC) Formula
Formula: Yield on Cost = Annual Dividend / Original Purchase Price × 100
Inputs shown in the projection:
- Original purchase price.
- Annual dividend per share at the starting point.
- Assumed annual dividend growth rate.
- Projected annual dividend divided by original purchase price.
Note: Forward projections assume dividends continue to grow at the designated growth rate. Actual dividend payments are declared by corporate boards and are subject to change.
Moderna, Inc. Yield on Cost (YOC) Formula & Definition
Yield on Cost shows the dividend yield based on your original purchase price. As dividends grow, your YOC increases even if the market yield stays the same.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel